{"id":111619,"date":"2025-05-22T18:13:00","date_gmt":"2025-05-22T21:13:00","guid":{"rendered":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/boehringer-ingelheim-to-present-early-clinical-evidence-of-innate-immune-modulation-and-anti-tumor-activity-via-sirp-blockade-in-two-ongoing-trials-at-asco-2025\/"},"modified":"2025-05-22T18:13:00","modified_gmt":"2025-05-22T21:13:00","slug":"boehringer-ingelheim-to-present-early-clinical-evidence-of-innate-immune-modulation-and-anti-tumor-activity-via-sirp-blockade-in-two-ongoing-trials-at-asco-2025","status":"publish","type":"post","link":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/releases\/releases-geral\/boehringer-ingelheim-to-present-early-clinical-evidence-of-innate-immune-modulation-and-anti-tumor-activity-via-sirp-blockade-in-two-ongoing-trials-at-asco-2025\/","title":{"rendered":"Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRP blockade in two ongoing trials at ASCO 2025"},"content":{"rendered":"<ul>\n<li data-mce-style=\"text-indent: -18pt;\" style=\"text-indent: -18pt\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%;font-family: Symbol\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-US;\"><span data-mce-style=\"mso-list: Ignore;\">\u00b7<span style=\"font: 7.0pt 'Times New Roman'\" data-mce-style=\"font: 7.0pt 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span><\/span><\/span><b data-mce-style=\"mso-bidi-font-weight: normal;\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: 'MS Gothic'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: major-bidi; mso-ansi-language: EN-US;\">BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second-line treatment in patients with recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC).<\/span><\/b><b data-mce-style=\"mso-bidi-font-weight: normal;\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: 'MS Gothic'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: major-bidi; mso-ansi-language: EN-US;\">\u00a0<\/span><\/b><\/li>\n<li data-mce-style=\"text-indent: -18pt;\" style=\"text-indent: -18pt\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%;font-family: Symbol\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;\"><span data-mce-style=\"mso-list: Ignore;\">\u00b7<span style=\"font: 7.0pt 'Times New Roman'\" data-mce-style=\"font: 7.0pt 'Times New Roman';\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span><\/span><\/span><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: 'MS Gothic'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: major-bidi; mso-ansi-language: EN-US;\">Next generation SIRP<\/span><\/b><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Cambria',serif\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Cambria',serif; mso-fareast-font-family: 'MS Gothic'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: Cambria; mso-ansi-language: EN-US;\"><\/span><\/b><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: 'MS Gothic'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: major-bidi; mso-ansi-language: EN-US;\"> inhibitor <a name=\"_Hlk198026644\" \/>BI 770371 was shown to be well tolerated alone and in combination with PD1 inhibitor ezabenlimab in a dose escalation trial in patients with advanced solid tumors. BI 770371 is currently being further investigated in a Phase 1b study in first-line patients with R\/M HNSCC.<\/span><\/b><b data-mce-style=\"mso-bidi-font-weight: normal;\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: 'MS Gothic'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: major-bidi; mso-ansi-language: EN-US;\">\u00a0<\/span><\/b><\/li>\n<\/ul>\n<p><b data-mce-style=\"mso-bidi-font-weight: normal;\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: 'MS Gothic'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: major-bidi; mso-ansi-language: EN-US;\">Ingelheim, Germany, 22 May 2025  <\/span><\/b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">Boehringer Ingelheim today announced that new clinical data from two early-stage trials targeting the signal regulatory protein <\/span><span style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Cambria',serif\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Cambria',serif; mso-bidi-font-family: Cambria;\"><\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\"> (SIRP<\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Cambria',serif\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Cambria',serif; mso-bidi-font-family: Cambria; mso-ansi-language: EN-US;\"><\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-bidi-font-family: Cambria; mso-ansi-language: EN-US;\">)<\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\"> innate immune checkpoint will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 &#8211; June 3, 2025, in Chicago, IL, USA.<\/span><span style=\"font-size: 10.5pt\" data-mce-style=\"font-size: 10.5pt;\">\u00a0<\/span><\/p>\n<p><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">In a Phase 1b study conducted by Boehringer, its potential, first-in-class SIRP<\/span><span style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Cambria',serif\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Cambria',serif; mso-bidi-font-family: Cambria;\"><\/span><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\"> <span lang=\"EN-US\">monoclonal antibody, BI 765063, demonstrated a manageable safety profile as well as preliminary signs of immune activation and additive antitumor activity when combined with PD-1 inhibitor ezabenlimab and cetuximab in patients with recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC).<a href=\"#_edn1\" name=\"_ednref1\" title=\"\" data-mce-style=\"mso-endnote-id: edn1;\" data-mce-href=\"#_edn1\"><span><span data-mce-style=\"mso-special-character: footnote;\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Boehringer Forward Text'\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Boehringer Forward Text'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Boehringer Forward Text'; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">[1]<\/span><\/span><\/span><\/a><\/span><\/span><span style=\"font-size: 10.5pt\" data-mce-style=\"font-size: 10.5pt;\">\u00a0<\/span><\/p>\n<p><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">Additionally, in an open-label, Phase I trial conducted by Boehringer, its next-generation SIRP<\/span><span style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Cambria',serif\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Cambria',serif; mso-bidi-font-family: Cambria;\"><\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\"> monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab, was shown to be well tolerated in patients with advanced solid tumors.<\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-bidi-font-weight: bold;\"> There were no dose-limiting toxicities in either treatment arm, and the maximum tolerated dose was not reached in either group.<a href=\"#_edn2\" name=\"_ednref2\" title=\"\" data-mce-style=\"mso-endnote-id: edn2;\" data-mce-href=\"#_edn2\"><span><span data-mce-style=\"mso-special-character: footnote;\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Boehringer Forward Text'\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Boehringer Forward Text'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Boehringer Forward Text'; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-bidi-font-weight: bold;\">[2]<\/span><\/span><\/span><\/a> <\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\"><span data-mce-style=\"mso-spacerun: yes;\">\u00a0<\/span><\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">\u00a0<\/span><\/p>\n<p><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">The preliminary results from these early-stage programs are encouraging and further strengthen Boehringers robust immuno-oncology pipeline aimed at accelerating next-generation cancer therapies to address high unmet patient needs, said Mike Akimov, Head of Medicine, Therapy Area Oncology at Boehringer Ingelheim. Boehringer is developing various complementary approaches to activate the immune system against cancer cells and<\/span><span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%;color: black;background: white\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-bidi-font-family: Calibri; color: black; background: white; mso-ansi-language: EN-US;\"> <\/span><\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">SIRP<\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Cambria',serif\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Cambria',serif; mso-bidi-font-family: Cambria; mso-ansi-language: EN-US;\"><\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\"> blockade paired with a PD-1 inhibitor is a promising strategy. We look forward to seeing if this dual activation may lead to a broader and more sustained anti-tumor response as the programs progress.<\/span><span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%;color: black;background: white\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-bidi-font-family: Calibri; color: black; background: white; mso-ansi-language: EN-US;\"> <\/span><\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\"><span data-mce-style=\"mso-spacerun: yes;\">\u00a0<\/span><b \/><\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">\u00a0<\/span><\/p>\n<p><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">BI 765063 and BI 770371 are designed to block the dont eat me signal that cancer cells use to hide from the immune system. By targeting SIRP<\/span><span style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Cambria',serif\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Cambria',serif; mso-bidi-font-family: Cambria;\"><\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">, these antibodies help immune cells like macrophages recognize and destroy tumor cells, bolstering the bodys natural defenses.<a href=\"#_edn3\" name=\"_ednref3\" title=\"\" data-mce-style=\"mso-endnote-id: edn3;\" data-mce-href=\"#_edn3\"><span><span data-mce-style=\"mso-special-character: footnote;\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Boehringer Forward Text'\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Boehringer Forward Text'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Boehringer Forward Text'; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">[3]<\/span><\/span><\/span><\/a><\/span><span style=\"font-size: 10.5pt\" data-mce-style=\"font-size: 10.5pt;\">\u00a0<\/span><\/p>\n<p><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">Both antibodies have been developed in partnership with OSE, with Boehringer solely responsible for future clinical development and commercialization. Boehringer will move forward with the improved next generation SIRP<\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Cambria',serif\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Cambria',serif; mso-bidi-font-family: Cambria; mso-ansi-language: EN-US;\"><\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\"> inhibitor antibody BI 770371, which will now be tested in a Phase 1b study.<\/span><\/p>\n<p><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">\u00a0<\/span><\/p>\n<p><b><u><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">Presentation Details:<\/span><\/u><\/b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">\u00a0<\/span><\/p>\n<p><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">Title: <\/span><\/b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">An Open-Label, Phase Ib Trial of the SIRP<\/span><span style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Cambria',serif\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Cambria',serif; mso-bidi-font-family: Cambria;\"><\/span><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\"> <span lang=\"EN-US\">Inhibitor BI 765063 in Combination with the PD-1 Inhibitor Ezabenlimab and Cetuximab in Patients (pts) with Head and Neck Squamous Cell Carcinoma <\/span><\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Times New Roman',serif\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Times New Roman',serif; mso-ansi-language: EN-US;\"><\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\" \/><\/p>\n<p><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">Abstract Number: <\/span><\/b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">6019<\/span><\/p>\n<p><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">Session Type\/Title:<\/span><\/b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\"> Rapid Oral Abstract  Developmental Therapeutics  Immunotherapy<\/span><\/p>\n<p><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">Date\/Time:<\/span><\/b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\"> 01 June 2025  11:30am  1:30pm CDT<b \/><\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">\u00a0<\/span><\/p>\n<p><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">Title: <\/span><\/b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">An Open-label, Phase I Trial of the SIRP<\/span><span style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Cambria',serif\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Cambria',serif; mso-bidi-font-family: Cambria;\"><\/span><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\"> <span lang=\"EN-US\">Monoclonal Antibody, BI 770371, Alone and in Combination with the PD-1 Inhibitor Ezabenlimab in Patients with Advanced Solid Tumors<b \/><\/span><\/span><\/p>\n<p><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">Abstract Number: <\/span><\/b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">2515<\/span><\/p>\n<p><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">Session Type\/Title:<\/span><\/b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\"> Rapid Oral Abstract  Developmental Therapeutics  Immunotherapy<\/span><\/p>\n<p><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">Date\/Time:<\/span><\/b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\"> 01 June 2025  11:15am  12:45pm CDT<b \/><\/span><\/p>\n<p><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US;\">\u00a0<\/span><\/p>\n<p><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">Boehringer Ingelheim<\/span><\/b><\/p>\n<p><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industrys top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer Ingelheim takes a long-term perspective, embedding sustainability along the entire value chain. More than 54,500 employees serve over 130 markets to build a healthier, more sustainable and equitable tomorrow. Learn more at<\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%;font-family: 'Times New Roman',serif\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; font-family: 'Times New Roman',serif; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\"><\/span><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Zfy6C4a1pW7m4qRjqlLSyZdWT9Kv_7IlDZ6Wv0QkKxjV5Ww4nxD3RxL7pv7ejZ5gJQrGyJ-aNsY30sLzf-xol1gKRQjqO_KWn9kvK0BL_Bf2672wjZeFFpunx9BgjZt0UMK62uB2Fru4DKvJuQvTqw==\" target=\"_blank\" rel=\"noopener\" data-mce-href=\"https:\/\/www.boehringer-ingelheim.com\/\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">https:\/\/www.boehringer-ingelheim.com<\/span><\/a><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\"> (Global).\u00a0<\/span><\/p>\n<p><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">OSE Immunotherapeutics<\/span><\/b><\/p>\n<p><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&amp;I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext.<\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">\u00a0<\/span><\/p>\n<p><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">Additional information about OSE Immunotherapeutics assets is available on the Companys website: <\/span><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bOkBWlpRxNGWeFJcS2QRhhrjLqNk_PWT10m_3LyShoiFO00iuUlPl0D1_ylSqp0EesWkK--AZS9l-0LC6ORX9tUT4b3njjXs-skMh8AH_5Q=\" data-mce-href=\"http:\/\/www.ose-immuno.com\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">www.ose-immuno.com<\/span><\/a><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">. <span data-mce-style=\"mso-bidi-font-weight: bold;\">Click and follow us on LinkedIn.<\/span><\/span><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">\u00a0<\/span><\/b><\/p>\n<p><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">Intended Audiences Notice<\/span><\/b><\/p>\n<p><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.<\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">\u00a0<\/span><\/p>\n<p><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">Forward-looking statements<\/span><\/b><\/p>\n<p><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">This press release contains express or implied information and statements that might be deemed forward-looking information and<span data-mce-style=\"mso-bidi-font-weight: bold;\"> <\/span>statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.<\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">\u00a0<\/span><\/p>\n<p><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">These forward-looking statements include statements typically using conditional and containing verbs such as expect, anticipate, believe, target, plan, or estimate, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2024, including the annual financial report for the fiscal year 2023, available on the OSE Immunotherapeutics website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.<\/span><\/p>\n<p><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">\u00a0<\/span><\/p>\n<p><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW;\">Contacts<\/span><\/b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: EN-US; mso-bidi-font-weight: bold; mso-bidi-font-style: italic;\" \/><\/p>\n<p data-mce-style=\"margin-right: -2.9pt;\" style=\"margin-right: -2.9pt\"><b><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%;\">Boehringer Ingelheim<\/span><\/b><\/p>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"652\" data-mce-style=\"border-collapse: collapse; mso-table-layout-alt: fixed; mso-yfti-tbllook: 1184; mso-padding-alt: 0cm 0cm 0cm 0cm;\" style=\"border-collapse: collapse\">\n<tr data-mce-style=\"mso-yfti-irow: -1; mso-yfti-firstrow: yes; mso-yfti-lastfirstrow: yes; mso-yfti-lastrow: yes; page-break-inside: avoid;\">\n<td width=\"1\" valign=\"top\" style=\"width: 3.9px;padding: 0cm\" data-mce-style=\"width: 3.9px; padding: 0cm;\">\n<p data-mce-style=\"mso-yfti-cnfc: 1;\"><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%;\">\u00a0<\/span><\/p>\n<\/td>\n<td width=\"651\" valign=\"top\" style=\"width: 645.7px;padding: 0cm\" data-mce-style=\"width: 645.7px; padding: 0cm;\">\n<p data-mce-style=\"mso-yfti-cnfc: 1;\"><b><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: 'MS Gothic'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: major-bidi;\">Linda Ruckel<\/span><\/b><\/p>\n<p data-mce-style=\"mso-yfti-cnfc: 1;\"><b><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: 'MS Gothic'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: major-bidi;\">+1 203-791-6672<\/span><\/b><\/p>\n<p data-mce-style=\"mso-yfti-cnfc: 1;\"><a href=\"mailto:linda.ruckel@boehringer-ingelheim.com\" data-mce-href=\"mailto:linda.ruckel@boehringer-ingelheim.com\"><b><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: 'MS Gothic'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: major-bidi;\">linda.ruckel@boehringer-ingelheim.com<\/span><\/b><\/a><b><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: 'MS Gothic'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: major-bidi;\"> <\/span><\/b><\/p>\n<p data-mce-style=\"mso-yfti-cnfc: 1;\"><b><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: 'MS Gothic'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: major-bidi;\">Reinhard Malin<\/span><\/b><\/p>\n<p data-mce-style=\"mso-yfti-cnfc: 1;\"><a href=\"tel:+49%20(6132)%2077-90815\" data-mce-href=\"tel:+49%20(6132)%2077-90815\"><b><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: 'MS Gothic'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: major-bidi;\">+49 (6132) 77-90815<\/span><\/b><\/a><b><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: 'MS Gothic'; mso-fareast-theme-font: major-fareast; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: major-bidi;\"><br \/><\/span><\/b><a href=\"mailto:reinhard.malin@boehringer-ingelheim.com\" data-mce-href=\"mailto:reinhard.malin@boehringer-ingelheim.com\"><b><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%;\">reinhard.malin@boehringer-ingelheim.com<\/span><\/b><\/a><b><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%;\"> <span data-mce-style=\"mso-tab-count: 1;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span><\/span><\/b><span lang=\"FR\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-ansi-language: FR;\" \/><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p data-mce-style=\"margin-right: -2.9pt;\" style=\"margin-right: -2.9pt\"><b><span style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%;\">\u00a0<\/span><\/b><\/p>\n<p data-mce-style=\"mso-pagination: widow-orphan lines-together; page-break-after: avoid; margin: 0cm 2.4pt 6.0pt 0cm;\" style=\"margin: 0cm 2.4pt 6.0pt 0cm\"><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW;\">OSE Immunotherapeutics<\/span><\/b><\/p>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"612\" data-mce-style=\"width: 459.35pt; border-collapse: collapse; border: none; mso-yfti-tbllook: 1184; mso-padding-alt: 0cm 5.4pt 0cm 5.4pt; mso-border-insideh: none; mso-border-insidev: none;\" style=\"width: 459.35pt;border-collapse: collapse;border: none\">\n<tr data-mce-style=\"mso-yfti-irow: 0; mso-yfti-firstrow: yes; mso-yfti-lastrow: yes;\">\n<td width=\"205\" valign=\"top\" style=\"width: 154.05pt;padding: 0cm 5.4pt 0cm 5.4pt\" data-mce-style=\"width: 154.05pt; padding: 0cm 5.4pt 0cm 5.4pt;\">\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"612\" data-mce-style=\"width: 459.35pt; border-collapse: collapse; border: none; mso-yfti-tbllook: 1184; mso-padding-alt: 0cm 5.4pt 0cm 5.4pt; mso-border-insideh: none; mso-border-insidev: none;\" style=\"width: 459.35pt;border-collapse: collapse;border: none\">\n<tr data-mce-style=\"mso-yfti-irow: 0; mso-yfti-firstrow: yes; mso-yfti-lastrow: yes;\">\n<td width=\"208\" valign=\"top\" style=\"width: 155.95pt;padding: 0cm 5.4pt 0cm 5.4pt\" data-mce-style=\"width: 155.95pt; padding: 0cm 5.4pt 0cm 5.4pt;\">\n<p data-mce-style=\"margin-right: 2.4pt; mso-pagination: widow-orphan lines-together; page-break-after: avoid;\" style=\"margin-right: 2.4pt\"><b data-mce-style=\"mso-bidi-font-weight: normal;\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW;\">Fiona Olivier<\/span><\/b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW; mso-bidi-font-weight: bold;\"><br \/>fiona.olivier@ose-immuno.com<\/span><\/p>\n<p data-mce-style=\"margin-right: 2.4pt; mso-pagination: widow-orphan lines-together; page-break-after: avoid;\" style=\"margin-right: 2.4pt\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW; mso-bidi-font-weight: bold;\">\u00a0<\/span><\/p>\n<p data-mce-style=\"margin-right: 2.4pt; mso-pagination: widow-orphan lines-together; page-break-after: avoid;\" style=\"margin-right: 2.4pt\"><b data-mce-style=\"mso-bidi-font-weight: normal;\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW;\">Sylvie D\u00e9try<\/span><\/b><\/p>\n<p data-mce-style=\"margin-right: 2.4pt; mso-pagination: widow-orphan lines-together; page-break-after: avoid;\" style=\"margin-right: 2.4pt\"><a href=\"mailto:sylvie.detry@ose-immuno.com\" data-mce-href=\"mailto:sylvie.detry@ose-immuno.com\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;\">sylvie.detry@ose-immuno.com<\/span><\/a><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW;\" \/><\/b><\/p>\n<\/td>\n<td width=\"181\" valign=\"top\" style=\"width: 136.0pt;padding: 0cm 5.4pt 0cm 5.4pt\" data-mce-style=\"width: 136.0pt; padding: 0cm 5.4pt 0cm 5.4pt;\">\n<p data-mce-style=\"mso-pagination: widow-orphan lines-together; page-break-after: avoid; margin: 0cm 2.4pt .0001pt 3.1pt;\" style=\"margin: 0cm 2.4pt .0001pt 3.1pt\"><b data-mce-style=\"mso-bidi-font-weight: normal;\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW;\">French Media Contact <\/span><\/b><\/p>\n<p data-mce-style=\"mso-pagination: widow-orphan lines-together; page-break-after: avoid; margin: 0cm 2.4pt .0001pt 3.1pt;\" style=\"margin: 0cm 2.4pt .0001pt 3.1pt\"><b data-mce-style=\"mso-bidi-font-weight: normal;\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW;\">FP2COM<\/span><\/b><\/p>\n<p data-mce-style=\"mso-pagination: widow-orphan lines-together; page-break-after: avoid; margin: 0cm 2.4pt .0001pt 3.1pt;\" style=\"margin: 0cm 2.4pt .0001pt 3.1pt\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW; mso-bidi-font-weight: bold;\">Florence Portejoie<\/span><\/p>\n<p data-mce-style=\"mso-pagination: widow-orphan lines-together; page-break-after: avoid; margin: 0cm 2.4pt .0001pt 3.1pt;\" style=\"margin: 0cm 2.4pt .0001pt 3.1pt\"><a href=\"mailto:fportejoie@fp2com.fr\" data-mce-href=\"mailto:fportejoie@fp2com.fr\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;\">fportejoie@fp2com.fr<\/span><\/a><span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;\" \/><\/span><\/p>\n<p data-mce-style=\"margin-left: 3.1pt; mso-pagination: widow-orphan lines-together; page-break-after: avoid;\" style=\"margin-left: 3.1pt\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW; mso-bidi-font-weight: bold;\">+33\u00a06 07\u00a0768\u00a0283<\/span><\/p>\n<\/td>\n<td width=\"223\" valign=\"top\" style=\"width: 167.4pt;padding: 0cm 5.4pt 0cm 5.4pt\" data-mce-style=\"width: 167.4pt; padding: 0cm 5.4pt 0cm 5.4pt;\">\n<p data-mce-style=\"margin-left: 1.8pt; line-height: 107%;\" style=\"margin-left: 1.8pt;line-height: 107%\"><b data-mce-style=\"mso-bidi-font-weight: normal;\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 107%\" data-mce-style=\"font-size: 10.5pt; line-height: 107%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW;\">U.S. Media Contact<\/span><\/b><\/p>\n<p data-mce-style=\"margin-left: 1.8pt; line-height: 107%;\" style=\"margin-left: 1.8pt;line-height: 107%\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 107%\" data-mce-style=\"font-size: 10.5pt; line-height: 107%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW; mso-bidi-font-weight: bold;\">Rooney Partners LLC<br \/>Kate Barrette<\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 107%\" data-mce-style=\"font-size: 10.5pt; line-height: 107%; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;\"><br \/><\/span><a href=\"mailto:kbarrette@rooneypartners.com\" target=\"_blank\" rel=\"noopener\" data-mce-href=\"mailto:kbarrette@rooneypartners.com\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 107%\" data-mce-style=\"font-size: 10.5pt; line-height: 107%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US;\">kbarrette@rooneypartners.com<\/span><\/a><u><span lang=\"ES\" style=\"font-size: 10.5pt;line-height: 107%\" data-mce-style=\"font-size: 10.5pt; line-height: 107%; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: ES;\" \/><\/u><\/p>\n<p data-mce-style=\"margin-left: 1.8pt; line-height: 107%;\" style=\"margin-left: 1.8pt;line-height: 107%\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 107%\" data-mce-style=\"font-size: 10.5pt; line-height: 107%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW; mso-bidi-font-weight: bold;\">+1 212 223 0561<\/span><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 107%\" data-mce-style=\"font-size: 10.5pt; line-height: 107%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW;\" \/><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p data-mce-style=\"margin-right: 2.4pt; mso-pagination: widow-orphan lines-together; page-break-after: avoid;\" style=\"margin-right: 2.4pt\"><b><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW;\" \/><\/b><\/p>\n<\/td>\n<td width=\"190\" valign=\"top\" style=\"width: 142.85pt;padding: 0cm 5.4pt 0cm 5.4pt\" data-mce-style=\"width: 142.85pt; padding: 0cm 5.4pt 0cm 5.4pt;\">\n<span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW; mso-bidi-font-weight: bold;\">\u00a0<\/span><\/p>\n<\/td>\n<td width=\"217\" valign=\"top\" style=\"width: 162.45pt;padding: 0cm 5.4pt 0cm 5.4pt\" data-mce-style=\"width: 162.45pt; padding: 0cm 5.4pt 0cm 5.4pt;\">\n<p data-mce-style=\"mso-pagination: widow-orphan lines-together; page-break-after: avoid; margin: 0cm 2.4pt 6.0pt 0cm;\" style=\"margin: 0cm 2.4pt 6.0pt 0cm\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW;\">\u00a0<\/span><\/p>\n<p data-mce-style=\"mso-pagination: widow-orphan lines-together; page-break-after: avoid; margin: 0cm 2.4pt 6.0pt 0cm;\" style=\"margin: 0cm 2.4pt 6.0pt 0cm\"><span lang=\"EN-US\" style=\"font-size: 10.5pt;line-height: 105%\" data-mce-style=\"font-size: 10.5pt; line-height: 105%; mso-fareast-font-family: PMingLiU; mso-bidi-font-family: 'Boehringer Forward Text'; mso-bidi-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: ZH-TW;\">\u00a0<\/span><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><span lang=\"EN-US\" data-mce-style=\"mso-ansi-language: EN-US; mso-bidi-font-style: italic;\">\u00a0<\/span><\/p>\n<div data-mce-style=\"mso-element: endnote-list;\"><\/p>\n<hr align=\"left\" size=\"1\" width=\"33%\" \/>\n<div id=\"edn1\" data-mce-style=\"mso-element: endnote;\">\n<span><span data-mce-style=\"mso-special-character: footnote;\"><span style=\"font-size: 8.0pt;line-height: 105%;font-family: 'Boehringer Forward Text'\" data-mce-style=\"font-size: 8.0pt; mso-bidi-font-size: 10.0pt; line-height: 105%; font-family: 'Boehringer Forward Text'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Boehringer Forward Text'; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: DE; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">[1]<\/span><\/span><\/span><span data-mce-style=\"mso-ansi-language: EN-US;\"> <\/span><a href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT491868\" data-mce-href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT491868\"><span lang=\"EN-US\" data-mce-style=\"mso-ansi-language: EN-US;\">An open-label, phase Ib trial of the SIRP<\/span><span style=\"font-family: 'Cambria',serif\" data-mce-style=\"font-family: 'Cambria',serif; mso-bidi-font-family: Cambria;\"><\/span><span lang=\"EN-US\" data-mce-style=\"mso-ansi-language: EN-US;\"> inhibitor BI 765063 in combination with the PD-1 inhibitor ezabenlimab and cetuximab in patients (pts) with head and neck squamous cell carcinoma. &#8211; ASCO<\/span><\/a><span lang=\"EN-US\" data-mce-style=\"mso-ansi-language: EN-US;\" \/><\/p>\n<p><span><span style=\"font-size: 10.0pt;line-height: 105%;font-family: 'Boehringer Forward Text'\" data-mce-style=\"font-size: 10.0pt; mso-bidi-font-size: 11.0pt; line-height: 105%; font-family: 'Boehringer Forward Text'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Boehringer Forward Text'; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: DE; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"><span data-mce-style=\"mso-special-character: footnote;\">[1]<\/span><\/span><\/span><span style=\"font-size: 10.0pt;line-height: 105%;font-family: 'Boehringer Forward Text'\" data-mce-style=\"font-size: 10.0pt; mso-bidi-font-size: 11.0pt; line-height: 105%; font-family: 'Boehringer Forward Text'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Boehringer Forward Text'; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"> <\/span><span style=\"font-size: 10.0pt;line-height: 105%;font-family: 'Boehringer Forward Text'\" data-mce-style=\"font-size: 10.0pt; mso-bidi-font-size: 11.0pt; line-height: 105%; font-family: 'Boehringer Forward Text'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Boehringer Forward Text'; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: DE; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\"><a href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT487306\" data-mce-href=\"https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT487306\"><span lang=\"EN-US\" data-mce-style=\"mso-ansi-language: EN-US;\">An open-label, phase I trial of the SIRP<\/span><span style=\"font-family: 'Cambria',serif\" data-mce-style=\"font-family: 'Cambria',serif; mso-bidi-font-family: Cambria;\"><\/span><span lang=\"EN-US\" data-mce-style=\"mso-ansi-language: EN-US;\"> monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors. &#8211; ASCO<\/span><\/a><\/span><\/p>\n<\/div>\n<div id=\"edn3\" data-mce-style=\"mso-element: endnote;\">\n<a href=\"#_ednref3\" name=\"_edn3\" title=\"\" data-mce-style=\"mso-endnote-id: edn3;\" data-mce-href=\"#_ednref3\"><span><span data-mce-style=\"mso-special-character: footnote;\">&lt;span style=&quot;font-size: 8.0pt; mso-bidi-font-size: 10.0pt; line-height: 105%; font-family: &#039;Boehringer Forward Text&#039;; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: &#039;Boehringer Forward Text&#039;; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-b<\/p>\n","protected":false},"excerpt":{"rendered":"\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibo","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[34],"tags":[],"class_list":["post-111619","post","type-post","status-publish","format-standard","hentry","category-releases-geral"],"acf":[],"_links":{"self":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/111619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/comments?post=111619"}],"version-history":[{"count":0,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/posts\/111619\/revisions"}],"wp:attachment":[{"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/media?parent=111619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/categories?post=111619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bluestudio.estadao.com.br\/agencia-de-comunicacao\/wp-json\/wp\/v2\/tags?post=111619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}